According to Nature, Mikhail Blagosklonny is a scientist, and majors in cancer and aging studies. He is the current professor of oncology at the Roswell Park for cancer patients. Mikhail Blagosklonny also was known as “Mish” and has a master’s degree and Ph.D. in experimental medicine and cardiology. He studied in the First Pavlov State Medical University of St. Petersburg.
After completing his studies, he got nominated as the associate professor of medicine at New York Medical College in 2002. He later became the senior scientist at Ordway Research Institute still in New York until 2009 when he assumed his new role at Roswell Park. He majors in cancer studies, cancer therapies, aging and anti-aging drugs.
According to Impact Journals, Mikhail Blagosklonny is the chief editor of the aging cell cycle and the Oncortaget. He is also a proud member of the editorial board that deals with the cells death research and differentiation.
Also, he is an associate editor of the cancer biology and therapy publications. Mikhail Blagosklonny has edited and published more than 270 papers in peer-reviewed journals and close to 25,000 citations giving him a credit record in his career.
Mikhail has a broad range of research interests that tackles molecular and cellular biology, clinical investigations, cell cycle, apoptosis, signal transduction, anticancer therapies, and drug resistance.
Mikhail Blagosklonny’s role at the Roswell is to monitor the cancer patients and a therapist, ensuring that they are well treated and attended to. He also deals with aging issues, advising patients on the appropriate anti-aging measures and issuing the anti-aging drugs.
He intends to take a new role on TOR signaling in cancer and aging. He is believed to be the best candidate to take on the role as he has the adequate knowledge and experience needed. He formulated the hypothesis and proposed the use of rapamycin drug for life extension.